Representing America’s biopharma & biotech companies. Shaping policy so science thrives & patients benefit.
Joined February 2010
- Tweets 16,911
- Following 52
- Followers 80,385
- Likes 3,083
2,473 Photos and videos
Today, we launched a new campaign to highlight how the 340B hospital markup program is a goldmine for big nonprofit hospital systems.
With no rules or transparency, hospitals can spend on luxury perks while patients face higher bills.
Washington needs to fix 340B!
6
3
2,156
The U.S. is at risk of losing its lead in medical innovation. While we debate MFN price controls, China is accelerating clinical trials and expanding its leadership in oncology and immunotherapy.
If we hand over the future of medicine to China, patients will pay the price.
Read more here: ow.ly/86xc50Z9XcZ
1
1
395
77% of insured Americans said they were interested in learning more about new websites that allow patients to purchase medicines directly from manufacturers.
Can you relate? Visit America’s Medicines to see how greater transparency helps patients navigate health care decisions.
294
This week, biopharmaceutical researchers met with over 175 policymaker offices.
We are incredibly grateful to the researchers who lent their voices to protect the ecosystem that enables life-saving science. #PhRMAFlyIn26
ow.ly/cPJc50ZaE5F
407
Today, our researchers are heading to Capitol Hill to meet directly with lawmakers and congressional staff to advocate for the pro-innovation policies that ensure America stays a global leader in medical discovery. #PhRMAFlyIn26
1
1
1
456
Our researchers are convening in DC today for #PhRMAFlyIn26!
Tomorrow, they will go to Capitol Hill to advocate for the policies needed to deliver new treatments to patients.
Follow along on Instagram
>>> ow.ly/S0iF50Z9ubx
1
386
Patients in other high-income countries have access to just 36% of new medicines. U.S. patients have access to 88%.
That gap is driven by policy choices that delay or restrict access.
We need policies that support innovation and ensure patients get the treatments they need.
1
3
3,133
Today is National Cancer Survivors Day, a time to celebrate life, honor resilience and look ahead at the incredible science bringing hope to millions.
Hear from some of our companies on the future of cancer treatments and the investments being made to deliver new treatments and new tomorrows for so many patients.
ow.ly/Fx4U50Z89us
1
727
Cell and gene therapies are changing the future of medicine.
But many Medicare patients still face barriers to accessing these innovative treatments. Our health care system must keep pace with innovation so patients can benefit from these breakthroughs.
1
1
548
Hospitals are converting to nonprofits to tap 340B revenue.
This begs the question: is this massive federal program supporting patients or being exploited to boost hospital profits? ow.ly/Fin850Z8aZI
1
657
June is Alzheimer’s & Brain Awareness Month — a time to recognize the millions of patients, families and caregivers impacted by Alzheimer’s disease and renew our commitment to advancing new treatments and cures.
For decades, Alzheimer’s was considered one of medicine’s greatest challenges. Today, scientific innovation is changing what’s possible.
1
375
As policymakers are considering harmful price control policies in the form of Most Favored Nation pricing, patients and caregivers are voicing their concerns.
Hear what they have to say: ow.ly/wkKU50Z84qR
429
On average, it takes 10 to 15 years and $2.6 billion to develop just one medicine, and only 12% of medicines entering clinical trials are successful in getting FDA approval.
IP protections, including patents, empower innovators to take on significant risks to develop the best medicines in the world.
ow.ly/XL4f50Z7OAm
630
Two decades ago, it took 16 years on average for a new medicine to have two competitors — now it takes an average of just two years.
The result — brand-to-brand competition — can lower the average cost of medicines by as much as 50%.
ow.ly/KvPh50Z7FkT
427
“Intellectual property doesn’t just protect ideas — it powers American jobs, strengthens local economies, and ensures the U.S. remains a global leader in innovation.”
PhRMA general counsel, Jim Stansel, lays out the far reaching impact of IP for medicine advancement: ow.ly/NmOj50Z7ElC
1
485
Today, American patients enjoy access to more treatment options than anywhere else in the world.
What do we have to thank for this success?
Two legal foundations: our intellectual property system and the Hatch-Waxman Act passed in 1984.
1
457
Patients should be able to access lower-cost medicines.
PBMs are increasingly excluding generics and biosimilars from formularies, limiting affordable options for patients.
ow.ly/k6sA50Z6Gsc
2
1
1,210
Importing foreign price controls means adopting discriminatory metrics that delay or deny patient care.
The U.S. must value the life of every patient and reject models that limit medical progress.
ow.ly/CG0Y50Z5zEA
1
709
Nearly 9 in 10 Americans say if they get seriously ill – they want to be in the U.S. for treatment.
While we continue to push for patients to be able to get the medicines they are prescribed, it’s important that we maintain the leadership in medical innovation that benefits every American.
ow.ly/SgAM50Z5z3u
2
2
6
1,211
Global competition in biopharmaceutical innovation is accelerating.
Countries like China are investing strategically and expanding R&D to lead in areas like oncology and advanced therapies.
The U.S. must stay focused on policies that ensure we continue to lead. #InvestInAmericaForum #cnbcevents
521
This National Cancer Research Month, we’re reminded that smart policies and sustained investment have made America the global leader in cancer research. Maintaining this important leadership is not guaranteed.
Let’s continue to bring next-generation cancer treatments to American patients.
ow.ly/QpAO50Z5gR8
2
612